Factors associated with multiple biologic switches in Axial Spondyloarthritis: Exploring real world clinical data with clustering analysis
Main Article Content
Abstract
Introduction: Axial Spondyloarthritis is a complex and heterogenousisorder. The disease varies significantly leading to a diverse spectrum of management choices. We analysed retrospective clinical data from our centre to identify factors associated with multiple biologic switches. We used clustering analysis, an unsupervised machine learning algorithm, and multivariate logistic regression.
Aim: To identify factors associated with a higher frequency of biologic switches in axial spondyloarthropathy patients in a real-world clinical setting.
Materials and Methods: Data were collected retrospectively from the consultations of 166 patients receiving biologic treatment for axial spondyloarthropathy at our centre from 2003 until 2021. Feature selection included: demographics; body mass index; clinical phenotype (axial involvement; peripheral arthritis; enthesitis; uveitis; psoriasis; inflammatory bowel disease); HLA-B27 positivity; radiographic disease; chronic widespread pain diagnosis; disease activity measures (baseline and aggregate scores over disease course) – Bath Ankylosing Spondylitis Disease Activity Index; Spinal pain Visual Analogue Score; Bath Ankylosing Spondylitis Functional Index; C-reactive protein; time to start biologic from diagnosis; number of biologics and mode of action. Clustering analysis included two additional variables: – response to Tumour Necrosis Factor inhibitors and Interleukin-17 inhibitors. Patients were defined as high biologic switchers if they received three or more biologics (not including non-medical switches to biosimilar agents). Multi-variate logistic regression was performed using MNLogit algorithm and clustering analysis using the k-means algorithm (Anaconda Distribution 2.7).
Results: Clustering partitioned our dataset into three clusters: Low Disease Burden (LDB), High Disease Burden 1(HDB1) and High Disease Burden 2(HDB2). The LDB cluster showed good response to treatment, lower disease activity scores and fewer treatment switches. HDB clusters had higher disease activity scores; however, the HDB1 patients had significantly fewer biologic switches. Common features of the HDB1 cluster were female sex, HLA-B27 negativity, less radiographic disease, and more chronic widespread pain diagnosis. Multivariate logistic regression showed that HLA-B27 positivity and higher disease activity scores were positively associated with more biologic switches, whereas time to start biologic and a diagnosis of chronic widespread pain were negatively associated.
Conclusion: HLA-B27 positivity, male sex, higher radiographic burden, higher disease activity scores and early biologic requirement were associated with more biologic switches. Females with axial spondyloarthropathy, HLA-B27 negativity and lower radiographic disease burden had significantly fewer biologic switches despite higher disease activity scores and were more likely to have accompanying chronic widespread pain. Despite advances in treatment, patients with high symptom burden pose a challenge in clinical practice. Consideration should be given to objective and holistic assessment of symptoms and treating other associated conditions, as necessary.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Bengtsson K, Forsblad-d’Elia H, Deminger A, Klingberg E, Dehlin M, Exarchou S, et al. Incidence of extra-articular manifestations in ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis: results from a national register-based cohort study. Rheumatol Oxf Engl. 2021 Jun 18;60(6):2725–34.
3. El Maghraoui A. Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications. Eur J Intern Med. 2011 Dec;22(6):554–60.
4. Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis. 2015 Jan;74(1):65–73.
5. Zhao SS, Radner H, Siebert S, Duffield SJ, Thong D, Hughes DM, et al. Comorbidity burden in axial spondyloarthritis: a cluster analysis. Rheumatol Oxf Engl. 2019 Oct 1;58(10):1746–54.
6. Son SM, Kim DS, Lee JS. Fibromyalgia in Axial Spondyloarthritis: A Meta-analysis. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis. 2022 Jan 1;28(1):e222–7.
7. Macfarlane GJ, Pathan E, Siebert S, Packham J, Gaffney K, Choy E, et al. AxSpA patients who also meet criteria for fibromyalgia: identifying distinct patient clusters using data from a UK national register (BSRBR-AS). BMC Rheumatol. 2019;3:19.
8. Rencber N, Saglam G, Huner B, Kuru O. Presence of Fibromyalgia Syndrome and Its Relationship with Clinical Parameters in Patients with Axial Spondyloarthritis. Pain Physician. 2019 Nov;22(6):E579–85.
9. Fernández‐Carballido C, Sanchez‐Piedra C, Valls R, Garg K, Sánchez‐Alonso F, Artigas L, et al. Female Sex, Age, and Unfavorable Response to Tumor Necrosis Factor Inhibitors in Patients With Axial Spondyloarthritis: Results of Statistical and Artificial Intelligence–Based Data Analyses of a National Multicenter Prospective Registry. Arthritis Care Res. 2023 Jan;75(1):115–24.
10. Kohn SO, Azam A, Hamilton LE, Harrison SR, Graef ER, Young KJ, et al. Impact of sex and gender on axSpA diagnosis and outcomes. Best Pract Res Clin Rheumatol. 2023 Sep;37(3):101875.
11. Rusman T, Van Bentum RE, Van Der Horst-Bruinsma IE. Sex and gender differences in axial spondyloarthritis: myths and truths. Rheumatology. 2020 Oct 1;59(Supplement_4):iv38–46.
12. Hanson A, Brown MA. Genetics and the Causes of Ankylosing Spondylitis. Rheum Dis Clin North Am. 2017 Aug;43(3):401–14.
13. Huang CH, Wei JCC, Chen CC, Chuang CS, Chou CH, Lin YJ, et al. Associations of the PTPN22 and CTLA-4 genetic polymorphisms with Taiwanese ankylosing spondylitis. Rheumatol Int. 2014 May;34(5):683–91.
14. Klavdianou K, Tsiami S, Baraliakos X. New developments in ankylosing spondylitis-status in 2021. Rheumatol Oxf Engl. 2021 Dec 24;60(Suppl 6):vi29–37.
15. Simone D, Al Mossawi MH, Bowness P. Progress in our understanding of the pathogenesis of ankylosing spondylitis. Rheumatol Oxf Engl. 2018 Aug 1;57(suppl_6):vi4–9.
16. Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res. 2019 Oct;71(10):1285–99.
17. Goswami RP, Sinha D, Chatterjee M, Bhadu D, Das S. Comparative Effectiveness of Tofacitinib and Adalimumab in Axial Spondyloarthritis: A Real-World Clinical Context Multicenter Study. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis. 2024 Jun 1;30(4):e108–14.
18. Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):19–34.
19. Danve A, O’Dell J. The ongoing quest for biomarkers in Ankylosing Spondylitis. Int J Rheum Dis. 2015 Nov;18(8):826–34.
20. Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994 Dec;21(12):2281–5.
21. Machado P, Landewé R, Lie E, Kvien TK, Braun J, Baker D, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis. 2011 Jan;70(1):47–53.
22. Bedaiwi M, Sari I, Thavaneswaran A, Ayearst R, Haroon N, Inman RD. Fatigue in Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Analysis from a Longitudinal Observation Cohort. J Rheumatol. 2015 Dec;42(12):2354–60.
23. Calin A, Edmunds L, Kennedy LG. Fatigue in ankylosing spondylitis--why is it ignored? J Rheumatol. 1993 Jun;20(6):991–5.
24. van Tubergen A, Black PM, Coteur G. Are patient-reported outcome instruments for ankylosing spondylitis fit for purpose for the axial spondyloarthritis patient? A qualitative and psychometric analysis. Rheumatology. 2015 Oct 1;54(10):1842–51.
25. Rosenbaum JT, Pisenti L, Park Y, Howard RA. Insight into the Quality of Life of Patients with Ankylosing Spondylitis: Real-World Data from a US-Based Life Impact Survey. Rheumatol Ther. 2019 Sep;6(3):353–67.
26. Liu F, Panagiotakos D. Real-world data: a brief review of the methods, applications, challenges and opportunities. BMC Med Res Methodol. 2022 Nov 5;22(1):287.
27. McLachlan GJ. Cluster analysis and related techniques in medical research. Stat Methods Med Res. 1992;1(1):27–48.
28. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994 Dec;21(12):2286–91.
29. Spoorenberg A, van der Heijde D, de Klerk E, Dougados M, de Vlam K, Mielants H, et al. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol. 1999 Apr;26(4):980–4.
30. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984 Apr;27(4):361–8.
31. Anaconda Software Distribution [Internet]. Anaconda Documentation. Anaconda Inc.; 2020.
32. Wang R, Dasgupta A, Ward MM. Predicting Probability of Response to Tumor Necrosis Factor Inhibitors for Individual Patients With Ankylosing Spondylitis. JAMA Netw Open. 2022 Mar 1;5(3):e222312.
33. Lorenzin M, Ortolan A, Frallonardo P, Oliviero F, Punzi L, Ramonda R. Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab. BMC Musculoskelet Disord. 2015 Jul 24;16:166.
34. Maneiro JR, Souto A, Salgado E, Mera A, Gomez-Reino JJ. Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis. RMD Open. 2015;1(1):e000017.
35. Pinto AS, Farisogullari B, Machado PM. Predictors of remission in people with axial spondyloarthritis: A systematic literature review. Semin Arthritis Rheum. 2022 Jul 27;56:152078.
36. Lee S, Kang S, Eun Y, Won HH, Kim H, Lee J, et al. Machine learning-based prediction model for responses of bDMARDs in patients with rheumatoid arthritis and ankylosing spondylitis. Arthritis Res Ther. 2021 Oct 9;23(1):254.
37. Benavent D, Franco-Gómez K, Plasencia-Rodriguez C, Novella-Navarro M, Bogas P, Nieto R, et al. Achievement rate and predictive factors of the recommended therapeutical target in patients with axial spondyloarthritis who remain on biological therapy: a prospective cohort study in Spain. BMJ Open. 2022 Apr 29;12(4):e057850.
38. Unal Enginar A. A comparison of the clinical characteristics and quality of life of male and female patients with non-radiographic axial spondyloarthritis. Int Immunopharmacol. 2023 Oct;123:110627.
39. Wright GC, Kaine J, Deodhar A. Understanding differences between men and women with axial spondyloarthritis. Semin Arthritis Rheum. 2020 Aug;50(4):687–94.
40. Li Z, van der Linden SM, Khan MA, Baumberger H, Zandwijk H van, Khan MK, et al. Heterogeneity of axial spondyloarthritis: genetics, sex and structural damage matter. RMD Open. 2022 May;8(1):e002302.
41. Roberts MJ, Hamrouni M, Linsley V, Moorthy A, Bishop NC. Exercise as an anti-inflammatory Therapy in Axial Spondyloarthritis Therapeutic Intervention (EXTASI) study: a randomized controlled trial. Rheumatol Adv Pract. 2024;8(2):rkae062.